Prim (LTS:0FP0) ROCE %: 11.69% (As of Dec. 2025)

What is Prim ROCE %?

Prim LTS:0FP0 71 ROCE % is 11.69% as of Dec. 2025. GuruFocus rates LTS:0FP0 with a GF Score™ of 71/100 and a GF Value™ of €7.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Prim's annualized ROCE % for the quarter that ended in Dec. 2025 was 11.69%.

Prim (LTS:0FP0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Prim ROCE % Related Terms

Prim ROCE % Historical Data

* Premium members only.

The historical data trend for Prim's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prim ROCE % Chart

Prim Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

17.86

8.26

13.02

10.84

15.39

Prim Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															9.99	13.64	8.35	19.32	11.69

71GF Score

Prim SA LTS:0FP0

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Prim ROCE % Calculation

Prim's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	22.347	/	( ( (190.276 - 49.407)	+	(196.532 - 47.067) )	/ 2 )
	=	22.347	/	( (140.869	+	149.465)	/ 2 )
	=	22.347	/	145.167
	=	15.39 %

Prim's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	17.162	/	( ( (207.939 - 63.751)	+	(196.532 - 47.067) )	/ 2 )
	=	17.162	/	( ( 144.188	+	149.465 )	/ 2 )
	=	17.162	/	146.8265
	=	11.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 11.69% mean?

Prim (LTS:0FP0) has a ROCE % of 11.69% as of Dec. 2025.

Is Prim's ROCE % too high?

Prim's current ROCE % is 11.69%. The Medical Devices & Instruments industry median ROCE % is 2.23. Prim's value of 11.69% is 424.2% above this industry median. Overall, Prim has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Prim's ROCE % compare to ISRG and BDX?

Prim's ROCE % of 11.69% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Prim's value of 11.69% is 424.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prim's current ROCE % of 11.69% is 424.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prim's current ROCE % is 11.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Prim stock overvalued right now?

Based on GuruFocus' analysis, Prim (LTS:0FP0) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.28, compared to a current price of €13.00 — trading 78.6% above its estimated fair value. The current ROCE % is 11.69% and 424.2% above the Medical Devices & Instruments industry median of 2.23. Prim's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Prim (LTS:0FP0), the current ROCE % is 11.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prim (LTS:0FP0) Overvalued in 2026?

Based on GuruFocus' analysis, Prim stock appears to be overvalued. The current stock price of €13.00 is trading 78.6% above its estimated GF Value™ of €7.28. GuruFocus considers Prim to be Significantly Overvalued.

Key valuation signals for LTS:0FP0:

ROCE %: 11.69%
GF Value™: €7.28 vs. price of €13.00 (78.6% above fair value)
GF Score™: 71/100 with 4 warning signs
Industry Position: 424.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the LTS:0FP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prim Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM XSWX:STMN XTER:SRT OCSE:COLO B NZSE:FPH SOLV ALGN COO BAX NSE:LENSKART ATR

Other Exchanges PRM:Spain 5P1:Germany

Address Calle F, numero 15, Poligono Industrial 1, Mostoles, Madrid, ESP, 28938

Website http://www.prim.es

Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.

71GF Score

Get the complete analysis for LTS:0FP0

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00

Price

€7.28

GF Value

View LTS:0FP0 Analysis

See ROCE % data for all stocks →